Provided by Tiger Trade Technology Pte. Ltd.

Roivant Sciences Ltd.

34.21
-0.5400-1.55%
Post-market: 34.210.00000.00%16:17 EDT
Volume:6.27M
Turnover:213.55M
Market Cap:24.71B
PE:-72.79
High:34.56
Open:34.28
Low:33.32
Close:34.75
52wk High:42.50
52wk Low:15.90
Shares:722.41M
Float Shares:581.00M
Volume Ratio:1.24
T/O Rate:1.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4700
EPS(LYR):-0.5400
ROE:-8.52%
ROA:-16.48%
PB:5.84
PE(LYR):-63.35

Loading ...

Roivant Sciences - Mosliciguat Shows Lower Cough Incidence than Placebo in Phocus Study

THOMSON REUTERS
·
Sep 08

Roivant Sciences Ltd - Mosliciguat Observed to be Well Tolerated with a Favorable Safety Profile

THOMSON REUTERS
·
Sep 08

Roivant Sciences Ltd - Study Also Met Its Secondary Endpoints at Week 16

THOMSON REUTERS
·
Sep 08

Roivant to Present Phase 2 PHocus Mosliciguat Topline Data in PH-ILD at ERS Congress Sept. 8, 2026

Reuters
·
Sep 06

Immunovant Holds Annual Stockholder Meeting with 96% Shares Represented

Reuters
·
Sep 04

J.P. Morgan Reaffirms Their Buy Rating on Roivant Sciences (ROIV)

TIPRANKS
·
Sep 02

Roivant Sciences President, Immunovant CEO Eric Venker Disposes of Common Shares Worth $7.15 Million

Reuters
·
Sep 02

NASD Most Active Issues

Dow Jones
·
Sep 01

Immunovant Director Atul Pande Disposes of 1,500 Common Shares Worth $64,905

Reuters
·
Aug 29

Roivant Sets Price for New Rare Disease Drug Lisraya at $35,000 a Month

Reuters
·
Aug 28

Lisraya is Commercially Available NOW - Roivant Presentation

THOMSON REUTERS
·
Aug 28

Roivant Sciences Exec Says Lisraya Will be Available at List Price of $35,000 for a 30-Day Supply

THOMSON REUTERS
·
Aug 28

Roivant Sciences Price Target Maintained with a $41.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 28

Roivant Sciences Gets FDA Approval for LISRAYA in Dermatomyositis; Shares Rise

MT Newswires Live
·
Aug 28

Priovant Therapeutics - Lisraya NOW Available in the U.S.

THOMSON REUTERS
·
Aug 28

Priovant Announces FDA Approval of Lisraya™ (Brepocitinib) for Adults with Dermatomyositis; NOW Available in the U.S.

THOMSON REUTERS
·
Aug 28

US FDA Approves Roivant-Priovant's Skin Disease Drug

Reuters
·
Aug 28

FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults

Reuters
·
Aug 28

FDA: Lisraya is the First FDA-Approved Oral Treatment Option for Patients with Dermatomyositis

THOMSON REUTERS
·
Aug 28

Roivant Says JAMA Dermatology Publishes Phase 3 VALOR Data Showing Brepocitinib Improves Dermatomyositis Skin Outcomes

Reuters
·
Aug 26